Kamat - Figure 30
MCNA in BCG-unresponsive Patients
FIG. 30: Another agent in the treatment of NMI bladder cancer is Mycobacterium phlei cell wall-nucleic acid complex (MCNA). A Phase 2 open-label study of MCNA in 129 patients included all patients who had failed BCG.[27] Among the BCG-unresponsive population, however, in a subgroup of 94 patients the overall 1-year disease-free survival (CR rate) was 34.8%. For CIS patients with/without papillary disease, disease-free survival at 1 year was 23.5%, and for patients with papillary only tumors, it was 61.2% at 1 year.
References
[27]
Li R, Amrhein J, Cohen A, et al. Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer. 2017;3:65–71 https://dx.doi.org/10.3233%2FBLC-160084